Sutro Biopharma, Inc. (STRO)
STRONASDAQ-GMBiotechnology: Biological Products (No Diagnostic Substances)
$10.61
+0.9900 (+10.29%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $175.93m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $7.15 to $43.85
- Average volume
- 314.0k
- Previous close
- $9.62
Analysts
9 coveringBuy8 buy, 0 hold, 1 sell
Targets a year out average $52.43, +394.2% from here
Earnings
next estimate $-1.88Next report
Mar 2026
-26.7%
Jun 2026
-14.2%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $9.69m | $11.65m | $14.52m | $9.84m |
| Gross profit | $9.69m | $11.65m | $14.52m | $9.84m |
| Operating income | -$48.46m | -$38.05m | -$29.66m | -$29.89m |
| Net income | -$56.86m | -$46.76m | -$38.48m | -$38.53m |
Last four quarters: revenue $45.70m, margin -395.3%, free cash flow –
News
8 latest- Here's Why Sutro Biopharma (STRO) is Poised for a Turnaround After Losing 34.2% in 4 WeeksZacks · 6 days ago
- Down 39.8% in 4 Weeks, Here's Why Sutro Biopharma (STRO) Looks Ripe for a Turnaround Zacks · 7 days ago
- Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue EstimatesZacks · Nov 2, 2026
- Sutro Announces Encouraging Early Clinical Activity From STRO-004 Phase 1 Study; Stock Down RTTNews · Aug 12, 2026
- Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue EstimatesZacks · Aug 11, 2026
- BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue EstimatesZacks · Aug 5, 2026
- Barclays Initiates Coverage of Sutro Biopharma (STRO) with Overweight RecommendationFintel · May 28, 2026
- Wedbush Upgrades Sutro Biopharma (STRO)Fintel · May 15, 2026
The company
Sutro Biopharma, Inc. is a clinical-stage biotechnology company advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro's cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what's possible in cancer therapy. The Company's pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- sutrobio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.